Innovative Drug Discovery Through a Three-Company Capital and Business Alliance with NanoCarrier and Noritsu Koki
First written in FY2018. 3 of 5 entries say "Restated". Latest entry: FY2020-Q1.
No other company in this theme has enough history to compare yet.
- FY2020-Q1RestatedAnnual report
「In April 2018, the Company entered into a capital and business alliance agreement with ナノキャリア and Noritsu Koki Co.,Ltd. and launched drug discovery activities under a collaborative framework among the 3 companies to create innovative technologies and pharmaceuticals by combining their respective technologies and expertise.」
We continue drug discovery activities conducted jointly by NanoCarrier, Noritsu Koki and the company. - FY2019RestatedAnnual report
「In April 2018, the Company entered into a capital and business alliance agreement with ナノキャリア and Noritsu Koki Co.,Ltd. and launched drug discovery activities through collaboration among the 3 companies to create innovative technologies and pharmaceuticals by combining their respective technologies and expertise.」
Continues activities to create innovative technologies and pharmaceuticals through collaboration among the 3 companies. - FY2019-Q2RestatedAnnual report
「In April 2018, we entered into a capital and business alliance agreement with ナノキャリア㈱ and Noritsu Koki Co.,Ltd. and began drug discovery activities under a three-company collaborative framework to create innovative technologies and pharmaceuticals by combining the technologies and expertise owned by each company.」
We continue drug discovery activities conducted jointly by NanoCarrier, Noritsu Koki and the company. - FY2019-Q1AdvancedAnnual report
「During the cumulative first quarter, the Company entered into a capital and business alliance agreement with ナノキャリア and Noritsu Koki Co.,Ltd. The 3 companies launched drug discovery activities under a collaborative framework to create innovative technologies and pharmaceuticals by combining their respective technologies and expertise, and have begun considering specific development products.」
The filing describes progress after the launch of the 3-company collaborative drug discovery activities, with the parties entering the stage of considering specific development products. - FY2018First statedAnnual report
「In April 2018, the Company entered into a capital and business alliance agreement with ナノキャリア, which owns Japan's cutting-edge micellar nanoparticle technology, and its parent company, Noritsu Koki Co.,Ltd. The 3 companies began drug discovery activities under a collaborative framework aimed at creating innovative technologies and pharmaceuticals by combining their respective technologies and expertise.」
The theme of drug discovery activities launched through collaboration among ナノキャリア, Noritsu Koki Co.,Ltd. and the Company, combining micellar nanoparticle technology and other technologies, appears for the first time.